Clinical trial

The Effect of Glucose-dependent Insulinotropic Polypeptide on the Alpha Cell Response to Hypoglycaemia in Patients with Type 1 Diabetes

NCT06137586

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

OTHER · Unmapped registry intervention Infusion of GIP[1-42], GIP[1-30] or placebo Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

The Effect of Glucose-dependent Insulinotropic Polypeptide on the Alpha Cell Response to Hypoglycaemia in Patients with Type 1 Diabetes

Design: INTERVENTIONAL · Status: COMPLETED · Phase: NA

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2022-08-10

PhaseNA

Conditions

Type1diabetesunresolved

Hypoglycemiaverified · MONDO: hypoglycemia

Type 1 Diabetesverified · MONDO: type 1 diabetes mellitus

Interventions

Infusion of GIP[1-42], GIP[1-30] or placeboOTHER

Sponsors & collaborators

University Hospital, Gentofte, Copenhagenlead sponsor

The Novo Nordisk Foundation Center for Basic Metabolic Researchcollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06137586 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.